Neurocrine Biosciences leads structurally, with valuation as the clearest single gap between the two profiles. GALD.SW still leads on profitability and stability, which keeps the comparison from looking entirely one-sided. In the market, GALD.SW carries the stronger setup — intact trend against Neurocrine Biosciences's broken trend. That leaves a split case: the structural lead stays with Neurocrine Biosciences, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels.
The comparison is mainly decided in valuation, with the rest of the profile carrying less weight.
Both operate in: Drug Manufacturers - Specialty & Generic
This comparison is based on industry proximity, not on functional trajectory similarity. GALD.SW and NBIX share the same industry classification.
For a similarity-based comparison, see how GALD.SW and Neurocrine Biosciences each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
Pricing shapes this comparison more than a broad operating gap.
Left means cheaper relative valuation. Higher means stronger structure.
GALD.SW looks stronger, but the price setup still looks more supportive for Neurocrine Biosciences, Inc..
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
The multiple-based pricing edge comes from a forward P/E that is 17.6 turns lower.
On the market side, GALD.SW carries the stronger trend while Neurocrine Biosciences's trend has broken — the market setup does not confirm the structural advantage.
Valuation points more clearly to Neurocrine Biosciences, Inc., but profitability and current pricing keep the broader result mixed.
Break down the GALD.SW vs NBIX comparison across all dimensions with the full interactive tool.
Explore how GALD.SW and NBIX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.